Immediate effects of risperidone on cerebral activity in healthy subjects: a comparison with subjects with first-episode schizophrenia
To test the hypothesis that administration of risperidone to healthy subjects produces reductions in metabolism in the frontal cortex similar to those produced by administration of risperidone to patients experiencing a first episode of schizophrenia. Positron emission tomography was used to measure...
Gespeichert in:
| Veröffentlicht in: | Journal of psychiatry & neuroscience 2004, Vol.29 (1), p.30-37 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 37 |
|---|---|
| container_issue | 1 |
| container_start_page | 30 |
| container_title | Journal of psychiatry & neuroscience |
| container_volume | 29 |
| creator | LANE, Carol J NGAN, Elton T. C YATHAM, Lakshmi N RUTH, Tom J LIDDLE, Peter F |
| description | To test the hypothesis that administration of risperidone to healthy subjects produces reductions in metabolism in the frontal cortex similar to those produced by administration of risperidone to patients experiencing a first episode of schizophrenia.
Positron emission tomography was used to measure the changes in regional metabolism produced by a single 2-mg dose of risperidone and by placebo, administered under randomized, double-blind conditions, in 9 healthy subjects. Conjunction analysis was used to identify those cerebral sites where changes in metabolism in the healthy subjects coincided with similar changes in metabolism observed in patients with schizophrenia.
Compared with placebo, risperidone produced reductions in metabolism in the left lateral frontal cortex and right medial frontal cortex in healthy subjects. Conjunction analysis revealed that these changes occurred at locations similar to the loci of change produced by risperidone in patients with schizophrenia.
Because the reduction in metabolism in the medial frontal cortex produced by risperidone is associated with alleviation of positive symptoms in patients with schizophrenia, the observation of a reduction in metabolism at a similar site in healthy subjects supports the hypothesis that the antipsychotic effect of risperidone arises, at least in part, from a physiologic effect that occurs in both patients with schizophrenia and healthy subjects. |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_305268</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>80094566</sourcerecordid><originalsourceid>FETCH-LOGICAL-p318t-3f28131ee40fea0133d90b9ad95917841cb9d7ca229bdb12f0379c88e0566d643</originalsourceid><addsrcrecordid>eNpdkc1q3TAQhU1JaNK0rxBEIN0Z9OdrKZBFCGkbCHTTrs1YHtW62JIjyQm3D9DnrkJu06YrzXC-o5nDvKmOmVSq5lLIg1IzRevS86PqXUpbSimnrHlbHTHZMk2lOq5-3c4zDg4yErQWTU4kWBJdWjC6IXgkwRODEfsIEwGT3YPLO-I8GRGmPO5IWvvtk--CADFhXqCYi-fR5fFFe-6siynXuBR9QJLM6H6GZYzoHbyvDi1MCT_s35Pq-6ebb9df6ruvn2-vr-7qRTCVa2G5YoIhSmoRKBNi0LTXMOhGs1ZJZno9tAY41_3QM26paLVRCmmz2QwbKU6qy-d_l7UvuQ36XHJ1S3QzxF0XwHWvFe_G7kd46ARt-EYV_8e9P4b7FVPuZpcMThN4DGvqFKVallkFPPsP3IY1-pKt46zlumFcFOj0321e1vhzngKc7wFIBiYbwRuX_nJN0wqphfgNRoqdgg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>217295123</pqid></control><display><type>article</type><title>Immediate effects of risperidone on cerebral activity in healthy subjects: a comparison with subjects with first-episode schizophrenia</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>LANE, Carol J ; NGAN, Elton T. C ; YATHAM, Lakshmi N ; RUTH, Tom J ; LIDDLE, Peter F</creator><creatorcontrib>LANE, Carol J ; NGAN, Elton T. C ; YATHAM, Lakshmi N ; RUTH, Tom J ; LIDDLE, Peter F</creatorcontrib><description>To test the hypothesis that administration of risperidone to healthy subjects produces reductions in metabolism in the frontal cortex similar to those produced by administration of risperidone to patients experiencing a first episode of schizophrenia.
Positron emission tomography was used to measure the changes in regional metabolism produced by a single 2-mg dose of risperidone and by placebo, administered under randomized, double-blind conditions, in 9 healthy subjects. Conjunction analysis was used to identify those cerebral sites where changes in metabolism in the healthy subjects coincided with similar changes in metabolism observed in patients with schizophrenia.
Compared with placebo, risperidone produced reductions in metabolism in the left lateral frontal cortex and right medial frontal cortex in healthy subjects. Conjunction analysis revealed that these changes occurred at locations similar to the loci of change produced by risperidone in patients with schizophrenia.
Because the reduction in metabolism in the medial frontal cortex produced by risperidone is associated with alleviation of positive symptoms in patients with schizophrenia, the observation of a reduction in metabolism at a similar site in healthy subjects supports the hypothesis that the antipsychotic effect of risperidone arises, at least in part, from a physiologic effect that occurs in both patients with schizophrenia and healthy subjects.</description><identifier>ISSN: 1180-4882</identifier><identifier>EISSN: 1488-2434</identifier><identifier>PMID: 14719048</identifier><identifier>CODEN: JPNEEF</identifier><language>eng</language><publisher>Ottawa, ON: Canadian Medical Association</publisher><subject>Adolescent ; Adult ; Antipsychotic Agents - pharmacokinetics ; Antipsychotic Agents - pharmacology ; Antipsychotic Agents - therapeutic use ; Biological and medical sciences ; Diagnostic and Statistical Manual of Mental Disorders ; Double-Blind Method ; Female ; Fluorodeoxyglucose F18 - pharmacokinetics ; Frontal Lobe - blood supply ; Frontal Lobe - drug effects ; Frontal Lobe - metabolism ; Health Status ; Humans ; Male ; Medical sciences ; Neuropharmacology ; Pharmacology. Drug treatments ; Psycholeptics: tranquillizer, neuroleptic ; Psychology. Psychoanalysis. Psychiatry ; Psychopharmacology ; Radiopharmaceuticals - pharmacokinetics ; Research Paper ; Risperidone - pharmacokinetics ; Risperidone - pharmacology ; Risperidone - therapeutic use ; Schizophrenia - diagnosis ; Schizophrenia - drug therapy ; Severity of Illness Index ; Tomography, Emission-Computed</subject><ispartof>Journal of psychiatry & neuroscience, 2004, Vol.29 (1), p.30-37</ispartof><rights>2004 INIST-CNRS</rights><rights>Copyright Canadian Medical Association Jan 2004</rights><rights>2004 Canadian Medical Association</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC305268/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC305268/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,4022,53790,53792</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=15573493$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/14719048$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>LANE, Carol J</creatorcontrib><creatorcontrib>NGAN, Elton T. C</creatorcontrib><creatorcontrib>YATHAM, Lakshmi N</creatorcontrib><creatorcontrib>RUTH, Tom J</creatorcontrib><creatorcontrib>LIDDLE, Peter F</creatorcontrib><title>Immediate effects of risperidone on cerebral activity in healthy subjects: a comparison with subjects with first-episode schizophrenia</title><title>Journal of psychiatry & neuroscience</title><addtitle>J Psychiatry Neurosci</addtitle><description>To test the hypothesis that administration of risperidone to healthy subjects produces reductions in metabolism in the frontal cortex similar to those produced by administration of risperidone to patients experiencing a first episode of schizophrenia.
Positron emission tomography was used to measure the changes in regional metabolism produced by a single 2-mg dose of risperidone and by placebo, administered under randomized, double-blind conditions, in 9 healthy subjects. Conjunction analysis was used to identify those cerebral sites where changes in metabolism in the healthy subjects coincided with similar changes in metabolism observed in patients with schizophrenia.
Compared with placebo, risperidone produced reductions in metabolism in the left lateral frontal cortex and right medial frontal cortex in healthy subjects. Conjunction analysis revealed that these changes occurred at locations similar to the loci of change produced by risperidone in patients with schizophrenia.
Because the reduction in metabolism in the medial frontal cortex produced by risperidone is associated with alleviation of positive symptoms in patients with schizophrenia, the observation of a reduction in metabolism at a similar site in healthy subjects supports the hypothesis that the antipsychotic effect of risperidone arises, at least in part, from a physiologic effect that occurs in both patients with schizophrenia and healthy subjects.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Antipsychotic Agents - pharmacokinetics</subject><subject>Antipsychotic Agents - pharmacology</subject><subject>Antipsychotic Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Diagnostic and Statistical Manual of Mental Disorders</subject><subject>Double-Blind Method</subject><subject>Female</subject><subject>Fluorodeoxyglucose F18 - pharmacokinetics</subject><subject>Frontal Lobe - blood supply</subject><subject>Frontal Lobe - drug effects</subject><subject>Frontal Lobe - metabolism</subject><subject>Health Status</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Neuropharmacology</subject><subject>Pharmacology. Drug treatments</subject><subject>Psycholeptics: tranquillizer, neuroleptic</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopharmacology</subject><subject>Radiopharmaceuticals - pharmacokinetics</subject><subject>Research Paper</subject><subject>Risperidone - pharmacokinetics</subject><subject>Risperidone - pharmacology</subject><subject>Risperidone - therapeutic use</subject><subject>Schizophrenia - diagnosis</subject><subject>Schizophrenia - drug therapy</subject><subject>Severity of Illness Index</subject><subject>Tomography, Emission-Computed</subject><issn>1180-4882</issn><issn>1488-2434</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpdkc1q3TAQhU1JaNK0rxBEIN0Z9OdrKZBFCGkbCHTTrs1YHtW62JIjyQm3D9DnrkJu06YrzXC-o5nDvKmOmVSq5lLIg1IzRevS86PqXUpbSimnrHlbHTHZMk2lOq5-3c4zDg4yErQWTU4kWBJdWjC6IXgkwRODEfsIEwGT3YPLO-I8GRGmPO5IWvvtk--CADFhXqCYi-fR5fFFe-6siynXuBR9QJLM6H6GZYzoHbyvDi1MCT_s35Pq-6ebb9df6ruvn2-vr-7qRTCVa2G5YoIhSmoRKBNi0LTXMOhGs1ZJZno9tAY41_3QM26paLVRCmmz2QwbKU6qy-d_l7UvuQ36XHJ1S3QzxF0XwHWvFe_G7kd46ARt-EYV_8e9P4b7FVPuZpcMThN4DGvqFKVallkFPPsP3IY1-pKt46zlumFcFOj0321e1vhzngKc7wFIBiYbwRuX_nJN0wqphfgNRoqdgg</recordid><startdate>2004</startdate><enddate>2004</enddate><creator>LANE, Carol J</creator><creator>NGAN, Elton T. C</creator><creator>YATHAM, Lakshmi N</creator><creator>RUTH, Tom J</creator><creator>LIDDLE, Peter F</creator><general>Canadian Medical Association</general><general>CMA Impact, Inc</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>3V.</scope><scope>4T-</scope><scope>4U-</scope><scope>7RV</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>88I</scope><scope>8AF</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8FQ</scope><scope>8FV</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M3G</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>2004</creationdate><title>Immediate effects of risperidone on cerebral activity in healthy subjects: a comparison with subjects with first-episode schizophrenia</title><author>LANE, Carol J ; NGAN, Elton T. C ; YATHAM, Lakshmi N ; RUTH, Tom J ; LIDDLE, Peter F</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p318t-3f28131ee40fea0133d90b9ad95917841cb9d7ca229bdb12f0379c88e0566d643</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Antipsychotic Agents - pharmacokinetics</topic><topic>Antipsychotic Agents - pharmacology</topic><topic>Antipsychotic Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Diagnostic and Statistical Manual of Mental Disorders</topic><topic>Double-Blind Method</topic><topic>Female</topic><topic>Fluorodeoxyglucose F18 - pharmacokinetics</topic><topic>Frontal Lobe - blood supply</topic><topic>Frontal Lobe - drug effects</topic><topic>Frontal Lobe - metabolism</topic><topic>Health Status</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Neuropharmacology</topic><topic>Pharmacology. Drug treatments</topic><topic>Psycholeptics: tranquillizer, neuroleptic</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopharmacology</topic><topic>Radiopharmaceuticals - pharmacokinetics</topic><topic>Research Paper</topic><topic>Risperidone - pharmacokinetics</topic><topic>Risperidone - pharmacology</topic><topic>Risperidone - therapeutic use</topic><topic>Schizophrenia - diagnosis</topic><topic>Schizophrenia - drug therapy</topic><topic>Severity of Illness Index</topic><topic>Tomography, Emission-Computed</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>LANE, Carol J</creatorcontrib><creatorcontrib>NGAN, Elton T. C</creatorcontrib><creatorcontrib>YATHAM, Lakshmi N</creatorcontrib><creatorcontrib>RUTH, Tom J</creatorcontrib><creatorcontrib>LIDDLE, Peter F</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>ProQuest Central (Corporate)</collection><collection>Docstoc</collection><collection>University Readers</collection><collection>Nursing & Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Canadian Business & Current Affairs Database</collection><collection>Canadian Business & Current Affairs Database (Alumni Edition)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>Research Library</collection><collection>Science Database</collection><collection>CBCA Reference & Current Events</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of psychiatry & neuroscience</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>LANE, Carol J</au><au>NGAN, Elton T. C</au><au>YATHAM, Lakshmi N</au><au>RUTH, Tom J</au><au>LIDDLE, Peter F</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Immediate effects of risperidone on cerebral activity in healthy subjects: a comparison with subjects with first-episode schizophrenia</atitle><jtitle>Journal of psychiatry & neuroscience</jtitle><addtitle>J Psychiatry Neurosci</addtitle><date>2004</date><risdate>2004</risdate><volume>29</volume><issue>1</issue><spage>30</spage><epage>37</epage><pages>30-37</pages><issn>1180-4882</issn><eissn>1488-2434</eissn><coden>JPNEEF</coden><abstract>To test the hypothesis that administration of risperidone to healthy subjects produces reductions in metabolism in the frontal cortex similar to those produced by administration of risperidone to patients experiencing a first episode of schizophrenia.
Positron emission tomography was used to measure the changes in regional metabolism produced by a single 2-mg dose of risperidone and by placebo, administered under randomized, double-blind conditions, in 9 healthy subjects. Conjunction analysis was used to identify those cerebral sites where changes in metabolism in the healthy subjects coincided with similar changes in metabolism observed in patients with schizophrenia.
Compared with placebo, risperidone produced reductions in metabolism in the left lateral frontal cortex and right medial frontal cortex in healthy subjects. Conjunction analysis revealed that these changes occurred at locations similar to the loci of change produced by risperidone in patients with schizophrenia.
Because the reduction in metabolism in the medial frontal cortex produced by risperidone is associated with alleviation of positive symptoms in patients with schizophrenia, the observation of a reduction in metabolism at a similar site in healthy subjects supports the hypothesis that the antipsychotic effect of risperidone arises, at least in part, from a physiologic effect that occurs in both patients with schizophrenia and healthy subjects.</abstract><cop>Ottawa, ON</cop><pub>Canadian Medical Association</pub><pmid>14719048</pmid><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1180-4882 |
| ispartof | Journal of psychiatry & neuroscience, 2004, Vol.29 (1), p.30-37 |
| issn | 1180-4882 1488-2434 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_305268 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Adolescent Adult Antipsychotic Agents - pharmacokinetics Antipsychotic Agents - pharmacology Antipsychotic Agents - therapeutic use Biological and medical sciences Diagnostic and Statistical Manual of Mental Disorders Double-Blind Method Female Fluorodeoxyglucose F18 - pharmacokinetics Frontal Lobe - blood supply Frontal Lobe - drug effects Frontal Lobe - metabolism Health Status Humans Male Medical sciences Neuropharmacology Pharmacology. Drug treatments Psycholeptics: tranquillizer, neuroleptic Psychology. Psychoanalysis. Psychiatry Psychopharmacology Radiopharmaceuticals - pharmacokinetics Research Paper Risperidone - pharmacokinetics Risperidone - pharmacology Risperidone - therapeutic use Schizophrenia - diagnosis Schizophrenia - drug therapy Severity of Illness Index Tomography, Emission-Computed |
| title | Immediate effects of risperidone on cerebral activity in healthy subjects: a comparison with subjects with first-episode schizophrenia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T07%3A25%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Immediate%20effects%20of%20risperidone%20on%20cerebral%20activity%20in%20healthy%20subjects:%20a%20comparison%20with%20subjects%20with%20first-episode%20schizophrenia&rft.jtitle=Journal%20of%20psychiatry%20&%20neuroscience&rft.au=LANE,%20Carol%20J&rft.date=2004&rft.volume=29&rft.issue=1&rft.spage=30&rft.epage=37&rft.pages=30-37&rft.issn=1180-4882&rft.eissn=1488-2434&rft.coden=JPNEEF&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E80094566%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=217295123&rft_id=info:pmid/14719048&rfr_iscdi=true |